RNAi-mediated Rab5a suppression inhibits proliferation and migration of vascular smooth muscle cells

Objective — The migration and proliferation of vascular smooth muscle cells (VSMC) are early and crucial events in the pathogenesis of intimal hyperplasia, the primary cause of restenosis after vascular reconstruction. We tested the hypothesis that down-regulation of Rab5a, a prototypical member of the Rab family of GTPases, leads to inhibition of VSMC proliferation and migration in the rat model. Methods — The intimal hyperplasia rat model was established and was used to test the expression of Rab5a at the vascular anastomoses at 7, 14 and 28 days post-operatively. The VSMCs were isolated from the thoracic aorta of SD rats and the expression of Rab5a was tested before and after exposure to RNAi by real-time PCR and Western blot.VSMC migration and proliferation were detected by flow cytometry using standard commercially available techniques and a Transwell chamber. Results — The rat models had significant stenosis at the anastomoses and the intima/media ratio was higher than that of the rat vessels. The expression of Rab5a was higher at the anastomotic site and peaked at 14 days after operation. The expression of Rab5a increased in the cultured VSMCs and decreased after RNAi. Proliferation and migration of VSMCs had been inhibited by down-regulating the expression of Rab5a. Conclusion — Aberrant expression of Rab5a can be found after vascular reconstruction and the proliferation and migration of VSMCs can be inhibited by RNAi silencing of Rab5a. This suggests the critical role for Rab5a in VSMCs proliferation and migration, and thus intimal hyperplasia and restenosis. Rab5a suppression might be a potential molecular therapeutic strategy to inhibit intimal hyperplasia.

[1]  U. Laufs,et al.  Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase* , 1998, The Journal of Biological Chemistry.

[2]  H. Feng,et al.  Over-expression of the RAB5 gene in human lung adenocarcinoma cells with high metastatic potential. , 1999, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[3]  G. Owens,et al.  Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury. , 2000, The Journal of clinical investigation.

[4]  E. Raines,et al.  The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease , 2000, International journal of experimental pathology.

[5]  B. Berk,et al.  Cyclophilin A Is Secreted by a Vesicular Pathway in Vascular Smooth Muscle Cells , 2006, Circulation research.

[6]  M. Rogers,et al.  Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  L. Machesky,et al.  Rab5 and Rac Team Up in Cell Motility , 2008, Cell.

[8]  Yingjin Yuan,et al.  Ferulic acid inhibits vascular smooth muscle cell proliferation induced by angiotensin II. , 2004, European journal of pharmacology.

[9]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[10]  N. Hayashi,et al.  Expression of Rab5a in hepatocellular carcinoma: Possible involvement in epidermal growth factor signaling , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  M. Davies,et al.  Pathobiology of intimal hyperplasia , 1994, The British journal of surgery.

[12]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[13]  E. Pieterman,et al.  Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. , 1999, Biochemical and biophysical research communications.

[14]  Kai Simons,et al.  The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway , 1992, Cell.

[15]  G. Owens,et al.  Molecular regulation of vascular smooth muscle cell differentiation in development and disease. , 2004, Physiological reviews.

[16]  Duan Ma,et al.  Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. , 2009, European journal of pharmacology.

[17]  P. Casey,et al.  Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.

[18]  W. Weintraub The pathophysiology and burden of restenosis. , 2007, The American journal of cardiology.

[19]  Giulio Gabbiani,et al.  Arterial Smooth Muscle Cell Heterogeneity: Implications for Atherosclerosis and Restenosis Development , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[20]  K. Karsch,et al.  Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. , 1990, Circulation research.

[21]  P. Delafontaine Growth factors and vascular smooth muscle cell growth responses. , 1998, European heart journal.

[22]  R. Ross Cellular and molecular studies of atherogenesis. , 1997, Atherosclerosis.

[23]  P. Stahl,et al.  Evidence for a Symmetrical Requirement for Rab5-GTP in in Vitro Endosome-Endosome Fusion* , 1998, The Journal of Biological Chemistry.

[24]  P. Serruys,et al.  Drug-Eluting Stent Update 2007: Part II: Unsettled Issues , 2007, Circulation.

[25]  A. Schmidt,et al.  Differentiation of coronary smooth muscle cells to a cell cycle-arrested hypertrophic growth status by a synthetic non-toxic heparin-mimicking compound. , 1999, Atherosclerosis.

[26]  M. Böhm,et al.  Reduction of Stenosis Due to Intimal Hyperplasia After Stent Supported Angioplasty of Peripheral Arteries by Local Administration of Paclitaxel in Swine , 2007, Investigative radiology.

[27]  P. Robinson,et al.  The small GTPases Rab5 and RalA regulate intracellular traffic of P-glycoprotein. , 2007, Biochimica et biophysica acta.

[28]  A. Llorente,et al.  Cholesterol regulates prostasome release from secretory lysosomes in PC-3 human prostate cancer cells. , 2007, European journal of cell biology.

[29]  A. Wells,et al.  Epidermal growth factor and membrane trafficking. EGF receptor activation of endocytosis requires Rab5a. , 2000 .

[30]  W. Seeger,et al.  Simvastatin Inhibits Inflammatory Properties of Staphylococcus aureus &agr;-Toxin , 2002, Circulation.

[31]  U. Laufs,et al.  Targeting Rho in cardiovascular disease. , 2000, Circulation research.